Toxic–Inflammatory Effects of Prostoglandin Analogs on the Ocular Surface

REFERENCES

• Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47:219–230.
   Web of Science ®Google Scholar
• Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–139.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806–1813. Epub 2011 Jul 2.
   PubMed Web of Science ®Google Scholar
• Mietz H, Schlötzer-Schrehardt U, Lemke JH, Krieglstein GK. Early conjunctival changes following treatment with metipranolol and preservatives are not reversible with dexamethasone. Graefes Arch Clin Exp Ophthalmol. 1997;235:452–459.
   Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556–563.
   PubMed Web of Science ®Google Scholar
• Baudouin C. The ocular surface in glaucoma. Cornea. 2009;28:14–19
   PubMed Web of Science ®Google Scholar
• Kierszenbaum AL, Tres LL. Blood and hematopoiesis. In: Histology and Cell Biology: An Introduction to Pathology. Philadelphia: Elsevier Saunders; 2012: 169–203.
   Google Scholar
• Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol. 2006;315:13–34.
   PubMedGoogle Scholar
• Kinra SL, Turlapati CS, Mehta CA, Lt Gen Ramji Rai. Study of p53 and bcl-2 oncoproteins in ulcerative colitis with dysplasia. MJAFI. 2005; 61:125–129.
   Google Scholar
• Turacli E, Budak K, Kaur A, Mizrak B. The effect of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol. 1997;21:27–33.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Riancho L, Liang H, Nakib Z, Baudouin C. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination. J Ocul Pharmacol Ther. 2011;27:273–280. Epub 2011 Mar 16.
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA. Effect of preservatives in chronic ocular therapy. Clin Refract Optometry. 2004;15:43–48.
   Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496.
   PubMed Web of Science ®Google Scholar
• Lumigan [package insert]. Irvine, CA: Allergan, Inc; 2006.
   Google Scholar
• Travatan [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2004.
   Google Scholar
• Xalatan [package insert]. New York: Pfizer Inc; 2003.
   Google Scholar
• Smith DL, Skuta GL, Kincaid MC, Rabbani R, Cruess DF, Kao SF. The effects of glaucoma medications on Tenon’s capsule and conjunctiva in the rabbit. Ophthalmic Surg. 1991;22:336–340.
   PubMedGoogle Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication, II: the outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446–54.
   PubMed Web of Science ®Google Scholar
• Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543–1548.
   PubMed Web of Science ®Google Scholar
• Aritürk N, Oge I, Baris S, Erkan D, Süllü Y, Koc F. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol. 1996;20:57–62.
   Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
   PubMed Web of Science ®Google Scholar
• Derous D, de Keizer RJ, de Wolff-Rouendaal D, Soudijn W. Conjunctival keratinization, an abnormal reaction to an ocular beta-blocker. Acta Ophthalmol (Copenh). 1989;67:333–338.
   Google Scholar
• Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Baudouin OB. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:4594–4599.
   PubMed Web of Science ®Google Scholar
• Mietz H, Niesen U, Krieglstein GK. The effects of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994;232:561–565.
   PubMed Web of Science ®Google Scholar
• Arıcı MK, Demircan S, Topalkara GC, Aker H, Arıcı DS. Effect of structure and inflammatory cell counts on intraocular pressure after trabeculectomy. Ophthalmologica. 1999;213:371–375.
   PubMed Web of Science ®Google Scholar
• Low SQ, Kitada S, Lee DA. lnterferon–γ inhibits collagen synthesis by human Tenon’s capsule fibroblasts in vitro. Invest Ophthalmol Vis Sci. 1991;32:2964–2969.
   Google Scholar
• Nagai N, Murao T, Okamoto N, Ito Y. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. J Oleo Sci. 2010;59:135–141.
   PubMed Web of Science ®Google Scholar
• Chyczewska E, Chyczewski L, Barczyk M, Kowal E. Morphology of mast cells in experimental pulmonary fibrosis induced with bleomysin. Pneumonol Alergol Pol. 1995;63:87–92.
   Google Scholar
• De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619–630.
   PubMed Web of Science ®Google Scholar
• Guenoun JM, Baudouin C, Rat P. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444–2450.
   PubMed Web of Science ®Google Scholar
• Rodrigues Mde L, Felipe Crosta DP, Soares CP, et al. Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment. J Glaucoma. 2009;18:197–200.
   Google Scholar
• Liang H, Baudouin C, Faure MO, Lambert G, Brignole-Baudouin F. Brignole-Baudouin F. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis. 2009;15:1690–1699.
   Google Scholar
• Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291–295.
   PubMedGoogle Scholar